{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:20:27Z","timestamp":1770333627785,"version":"3.49.0"},"reference-count":89,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"The authors have no funding to report"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2022,5,4]]},"DOI":"10.1080\/14737140.2022.2069564","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T11:46:38Z","timestamp":1651578398000},"page":"457-469","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022"],"prefix":"10.1080","volume":"22","author":[{"given":"Ravi Kumar","family":"Gupta","sequence":"first","affiliation":[{"name":"Larkin Community Hospital","place":["South Miami, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center","place":["Buffalo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center","place":["Buffalo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[{"name":"Division of Quantitative Health Sciences, Mayo Clinic","place":["Rochester, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alankrita","family":"Taneja","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center","place":["Buffalo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center","place":["Buffalo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"27","key":"e_1_3_4_2_1","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke C","unstructured":"Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016 Jul 11; 113(27\u201328):470\u2013476.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13038"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.897700"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14610"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-007-0134-y"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1221"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0440"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026548226770"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06405.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08573.x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-374249"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh300"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-451872"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.1.5.575"},{"key":"e_1_3_4_30_1","first-page":"1","article-title":"Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma","volume":"6","author":"Alegre A","year":"2011","unstructured":"Alegre A, Vicu\u00f1a I, Aguado B. Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol. 2011;6:1\u201310. December\/06.","journal-title":"Clin Med Insights Oncol"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0432-1"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213514468"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30140-0"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"issue":"1","key":"e_1_3_4_46_1","first-page":"437","article-title":"Update on a phase ii study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma","volume":"130","author":"Patel KK","unstructured":"Patel KK, Shah JJ, Feng L, et al. Update on a phase ii study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. Blood. [2017 Dec 7];130(Supplement 1):437.","journal-title":"Blood"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146798"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02060"},{"issue":"12","key":"e_1_3_4_50_1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol Internet]. 2021 Dec 1 cited 2021 Dec 27;22(12):1705\u20131720. Available from. https:\/\/pubmed.ncbi.nlm.nih.gov\/34774221\/","journal-title":"Lancet Oncol"},{"issue":"10","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau P","unstructured":"Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. Internet]. 2021 Oct 1 cited 2022 Apr 9;22(10):1378\u20131390. Available from:, http:\/\/www.thelancet.com\/article\/S1470204521004289\/fulltext","journal-title":"Lancet Oncol"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_4_53_1","volume-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (rvd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (ndmm): updated analysis of griffin after 24 months of maintenance","author":"Laubach J","year":"2021","unstructured":"Laubach J. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (rvd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (ndmm): updated analysis of griffin after 24 months of maintenance. : ASH; 2021 Abstract 79 ."},{"key":"e_1_3_4_54_1","article-title":"Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial","volume":"463","author":"Goldschmidt H","year":"2021","unstructured":"Goldschmidt H. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. ASH. 2021 Abstract 463 .","journal-title":"ASH"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139934"},{"key":"e_1_3_4_57_1","article-title":"Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: results from the Randomized Phase III GMMG-HD6 Trial","author":"Goldschmidt H","year":"2021","unstructured":"Goldschmidt H. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: results from the Randomized Phase III GMMG-HD6 Trial. ASH. 2021 Abstract 486 .","journal-title":"ASH"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00685"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO20203815suppl8506"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.09.008"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1473577"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0724-1"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"issue":"6","key":"e_1_3_4_65_1","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo M","unstructured":"Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. Internet]. 2020 Jun 1 cited 2022 Jan 5;7(6):e456\u201368. Available from:, https:\/\/pubmed.ncbi.nlm.nih.gov\/32359506\/","journal-title":"Lancet Haematol"},{"key":"e_1_3_4_66_1","first-page":"S10","article-title":"OAB-015: minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"21","author":"Rde T","unstructured":"Rde T, Pawlyn C, Cairns D, et al. OAB-015: minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk. Clin Lymphoma Myeloma Leukemia. 2021 Oct 1;21:S10.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"#cr-split#-e_1_3_4_67_1.1","unstructured":"Costa LJ Chhabra S Medvedova E et al. Daratumumab carfilzomib lenalidomide and dexamethasone with minimal residual disease Response-Adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol [Internet]. 2021 Dec 13 cited 2021 Dec 27]"},{"key":"#cr-split#-e_1_3_4_67_1.2","unstructured":"Available from 2021 Dec 27: https:\/\/pubmed.ncbi.nlm.nih.gov\/34898239\/"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1143.1143"},{"key":"e_1_3_4_70_1","volume-title":"Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial","author":"Jackson G","year":"2017","unstructured":"Jackson G, Davies FE, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial. Washington DC: American Society of Hematology; 2017."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1402888"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113001"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0273-x"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-725705"},{"issue":"7","key":"e_1_3_4_76_1","first-page":"1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt H","unstructured":"Goldschmidt H, Mai E, D\u00fcrig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020 Jul 1 34(7):1\u201313.","journal-title":"Leukemia"},{"key":"e_1_3_4_77_1","first-page":"2467","volume-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","author":"Pawlyn C","year":"2014","unstructured":"Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Vol. 124. United States: Blood.; 2014. p. 2467\u20132468."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0724-1"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309563"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0432-1"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1945578"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1334125"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110977"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9637"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO20193715.l8006"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.11.009"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2022.2069564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:32:20Z","timestamp":1770291140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2022.2069564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"alternative-id":["10.1080\/14737140.2022.2069564"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2022.2069564","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}